Interestingly, it has previously been shown that IGFBP-2 is regulated through PI3K/Akt in both malignant and non-malignant cells [33,34], while increased levels of IGFBP-2 have also been associated with a chemotherapy-resistant phenotype in AML [35]. This evidence concerns the gene AKT1 and acute myeloid leukemia.